Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Advanced Solid Tumors 3Solid Tumors 1Solid Malignancies 1Myelodysplastic Syndromes 1Leukemia 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Injections 18Carboplatin 14Docetaxel 11pembrolizumab 8durvalumab 7Cisplatin 6linifanib 5Paclitaxel 5Nivolumab 5zimberelimab 4talazoparib 4olaparib 4Panobinostat 4Itraconazole 4Bevacizumab 4tremelimumab 3sintilimab 3depatuxizumab 3atezolizumab 3ST 1481 3S 1 (combination) 3Rifampin 3Pemetrexed 3Oxaliplatin 3Fluorouracil 3Everolimus 3Drug Therapy 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors × ST 1481 × Clear all
NCT00410358 2020-12-19

A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.

Novartis

Phase 1 Completed
19 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00441610 2020-12-19

An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor

Novartis

Phase 1 Completed
4 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00487058 2009-11-19

A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
28 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡